Results 41 to 50 of about 14,464 (157)

Retinal pigment epithelium rip following single intravitreal ziv-aflibercept injection

Indian Journal of Ophthalmology, 2018
Sumit Randhir Singh, Jay Chhablani
doaj   +2 more sources

Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient

Thoracic Cancer, Volume 14, Issue 8, Page 779-782, March 2023., 2023
Small cell lung cancer patients presenting with metastasis of the iris are rare. Here, we report an extensive stage small cell lung cancer patient who presented with iris metastasis in the right eye and metastasis in the left adrenal gland as disease progression to first‐line chemotherapy plus atezolizumab.
Zhe Huang, Yongchang Zhang
wiley   +1 more source

The Inflation Reduction Act: A boon for the generic and biosimilar industry

Journal of Clinical Pharmacy and Therapeutics, Volume 47, Issue 11, Page 1738-1751, November 2022., 2022
The Inflation Reduction Act gives a significant boost to generics and biosimilars!Soon lowered out‐of‐pocket costBiosimilars promoted and adopted Abstract What is Known and Objective After more than a year of negotiation, a $740 billion climate and health care bill known as The Inflation Reduction Act (IRA) became law on 16 August 2022.
Sarfaraz K. Niazi
wiley   +1 more source

Efficacy and safety of Ziv-aflibercept in patients with central retinal vein occlusion

Delta Journal of Ophthalmology, 2021
Background Retinal vein occlusion is one of the most common vascular disorders that can cause visual loss. It is classified into central retinal vein occlusion (CRVO) and branch retinal vein occlusion.
Amin E Nawar, Heba M Shafik
doaj   +1 more source

Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations

Clinical Pharmacology &Therapeutics, Volume 112, Issue 4, Page 782-790, October 2022., 2022
Patients with cancer and advanced hepatic impairment (HI) (i.e., moderate and severe impairment) are often excluded from first‐in‐patient, phase II, and phase III studies. Thus, dose recommendations for this subgroup of patients are often derived using a combination of dedicated phase I studies conducted in participants without cancer and a population ...
Derek Z. Yang, Ali Alhadab, Kourosh Parivar, Diane D. Wang, Mohamed Elmeliegy   +4 more
wiley   +1 more source

Ziv-aflibercept in metastatic colorectal cancer. [PDF]

Biologics, 2014
The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF); it was approved in combination with
Patel A, Sun W.
europepmc   +6 more sources

Clinical management of metastatic colorectal cancer in the era of precision medicine

CA: A Cancer Journal for Clinicians, Volume 72, Issue 4, Page 372-401, July/August 2022., 2022
Abstract Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with localized disease eventually develop metastases.
Fortunato Ciardiello, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Josep Tabernero, Andres Cervantes   +5 more
wiley   +1 more source

The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study

Cancer Medicine, Volume 11, Issue 11, Page 2184-2192, June 2022., 2022
This multicenter retrospective study investigated whether a strategy of administering all available drugs leads to a better prognosis in metastatic colorectal cancer. Abstract Background The development of chemotherapy and treatment strategies for metastatic colorectal cancer (mCRC) have provided patients with significant survival benefits.
Takeshi Kawakami, Toshiki Masuishi, Yasuyuki Kawamoto, Hirofumi Go, Kyoko Kato, Ryosuke Kumanishi, Kentaro Sawada, Satoshi Yuki, Kouji Yamamoto, Yoshito Komatsu, Kei Muro, Kunihiro Fushiki, Hiromichi Shirasu, Kentaro Yamazaki   +13 more
wiley   +1 more source

Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration [PDF]

, 2020
Purpose:The aim of this study was to compare outcomes of 3 loading doses of ziv-aflibercept and aflibercept in treatment-naïve neovascular age-related macular degeneration (nAMD).Design:Retrospective, nonrandomized, comparative study.Methods:This was a ...
Subramanyam, Anand, Pandey, Priti, Chhablani, Jay Kumar, Abhishek Heranjal, Apoorva Ayachit, Tiwari, Sarvesh, Jay Chhablani, Heranjal, Abhishek, Sarvesh Tiwari, Salti, Haytham I.S., Priti Pandey, Ahmad Mansour, Ayachit, Apoorva G., Mansour, Ahmad Mohammed Farid Mahmoud, Chattannavar, Goura, Goura Chattannavar, Mohamad A Mansour, Sumit Randhir Singh, Anand Subramanyam, Haitham Salti, Singh, Sumit Randhir, Mansour, Mohamad A.   +21 more
core   +1 more source

A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer

Thoracic Cancer, Volume 13, Issue 10, Page 1463-1470, May 2022., 2022
Anlotinib (AL3818), an oral, small‐molecular tyrosine kinase inhibitor, was approved as a first third‐ and further‐line treatment regime of relapsed SCLC in China in 2019. This study showed that the addition of anlotinib to standard etoposide/platinum chemotherapy achieved encouraging PFS and OS in previously untreated extensive‐stage small cell lung ...
Chang Liu, Jiatao Liao, Xianghua Wu, Xinmin Zhao, Si Sun, Huijie Wang, Zhihuang Hu, Yao Zhang, Hui Yu, Jialei Wang   +9 more
wiley   +1 more source